Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.